{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:15:43Z","timestamp":1790129743945,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) severely limits clinical efficacy. Myeloid zinc finger 1 (MZF1) inhibited EGFR phosphorylation and internalization by maintaining zinc homeostasis, which suggested its potential as a therapeutic target for resensitization. The two MZF1 splice variants exhibited functional divergence. MZF1\n                    <jats:sup>S<\/jats:sup>\n                    demonstrated significantly reduced Zn\n                    <jats:sup>2+<\/jats:sup>\n                    -binding capacity compared with MZF1\n                    <jats:sup>L<\/jats:sup>\n                    owing to C\n                    <jats:sub>2<\/jats:sub>\n                    H\n                    <jats:sub>2<\/jats:sub>\n                    domain deletion. Although MZF1\n                    <jats:sup>S<\/jats:sup>\n                    was specifically upregulated in resistant patients, MZF1\n                    <jats:sup>L<\/jats:sup>\n                    predominated in treatment-sensitive cohorts, the mechanisms regulating their differential expression remained uncharacterized. We identified NSUN7\/YBX1-mediated RNA m\n                    <jats:sup>5<\/jats:sup>\n                    C methylation as a critical driver of resistance. This modification promoted competitive binding of SRSF1 over SRSF3 to MZF1 pre-mRNA and enhanced MZF1\n                    <jats:sup>S<\/jats:sup>\n                    production. Overlapping loci co-regulated by RNA m\n                    <jats:sup>5<\/jats:sup>\n                    C and DNA 5-methylcytosine methylation in the MZF1 5\u02b9-untranslated region suggested coordinated epigenetic control of alternative splicing. Characterization of these loci revealed a UHRF1\/DNMT1-NSUN7\/YBX1 axis that synergistically regulated splice variant selection. Targeting this axis suppressed MZF1\n                    <jats:sup>S<\/jats:sup>\n                    while restoring MZF1\n                    <jats:sup>L<\/jats:sup>\n                    expression, which resensitized resistant cells to EGFR-TKIs. Our findings established a dual-layer epigenetic mechanism governing alternative splicing in drug resistance and proposed methylation-regulated splice variants as biomarkers and therapeutic targets for overcoming EGFR-TKI resistance in non-small-cell lung cancer.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01758-4","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:17:39Z","timestamp":1782872259000},"page":"2138-2154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Coordinated DNA 5-mC and RNA m5C methylation epigenetically regulates MZF1 splice variants to drive EGFR-TKI resistance"],"prefix":"10.1038","volume":"58","author":[{"given":"Huan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0407-6486","authenticated-orcid":false,"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PanJian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuye","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1758_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1758_CR2","doi-asserted-by":"publisher","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin. Oncol. https:\/\/doi.org\/10.1038\/s41571-022-00639-9 (2022).","DOI":"10.1038\/s41571-022-00639-9"},{"key":"1758_CR3","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41419-020-03047-y","volume":"11","author":"Z Chen","year":"2020","unstructured":"Chen, Z. et al. Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1. Cell Death Dis. 11, 858 (2020).","journal-title":"Cell Death Dis."},{"key":"1758_CR4","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.1038\/s41388-019-0887-2","volume":"38","author":"S Raoof","year":"2019","unstructured":"Raoof, S. et al. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene 38, 6399\u20136413 (2019).","journal-title":"Oncogene"},{"key":"1758_CR5","doi-asserted-by":"publisher","first-page":"300060520954677","DOI":"10.1177\/0300060520954677","volume":"48","author":"GE Avram","year":"2020","unstructured":"Avram, G. E. et al. Changes in global DNA methylation and hydroxymethylation in oral mucosa according to tobacco smoke exposure. J. Int. Med. Res. 48, 300060520954677 (2020).","journal-title":"J. Int. Med. Res."},{"key":"1758_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s41388-020-01597-1","volume":"40","author":"FJ Cheng","year":"2021","unstructured":"Cheng, F. J. et al. Cigarette smoke-induced LKB1\/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC. Oncogene 40, 1162\u201375 (2021).","journal-title":"Oncogene"},{"key":"1758_CR7","doi-asserted-by":"publisher","unstructured":"Barth LM, Rink L, Wessels I. Increase of the intracellular zinc concentration leads to an activation and internalisation of the epidermal growth factor receptor in A549 cells. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22010326 (2020).","DOI":"10.3390\/ijms22010326"},{"key":"1758_CR8","doi-asserted-by":"publisher","unstructured":"Scheiermann E, Puppa MA, Rink L, Wessels I. Zinc status impacts the epidermal growth factor receptor and downstream protein expression in A549 cells. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23042270 (2022).","DOI":"10.3390\/ijms23042270"},{"key":"1758_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/cells9010223","volume":"9","author":"DM Brix","year":"2020","unstructured":"Brix, D. M., Bundgaard Clemmensen, K. K. & Kallunki, T. Zinc finger transcription factor MZF1-A specific regulator of cancer invasion. Cells 9, 223 (2020).","journal-title":"Cells"},{"key":"1758_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.7150\/ijbs.75963","volume":"19","author":"S Lin","year":"2023","unstructured":"Lin, S. et al. Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-\u03baB activity via UHRF1\/DNMT1 complex. Int. J. Biol. Sci. 19, 832\u2013851 (2023).","journal-title":"Int. J. Biol. Sci."},{"key":"1758_CR11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/1078-0432.CCR-18-1281","volume":"25","author":"Setal Lin","year":"2019","unstructured":"Lin, S. et al. Transcription factor myeloid zinc-finger 1 suppresses human gastric carcinogenesis by interacting with metallothionein 2A. Clin. Cancer Res. 25, 1050\u201362 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1758_CR12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00109-017-1578-5","volume":"95","author":"B Lin","year":"2017","unstructured":"Lin, B.et al. Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma. J. Mol. Med. 95, 1237\u201349 (2017).","journal-title":"J. Mol. Med."},{"key":"1758_CR13","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.apsb.2023.02.015","volume":"13","author":"S Lin","year":"2023","unstructured":"Lin, S. et al. UHRF1\/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of PRSS3 isoforms in lung cancer. Acta Pharm. Sin. B 13, 2086\u20132106 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"1758_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560\u2013562 (2015).","journal-title":"Nat. Med."},{"key":"1758_CR15","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin. Cancer Res. 26, 2654\u20132663 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1758_CR16","doi-asserted-by":"publisher","first-page":"6671","DOI":"10.1158\/1078-0432.CCR-19-1176","volume":"25","author":"E Pailler","year":"2019","unstructured":"Pailler, E. et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer. Clin. Cancer Res. 25, 6671\u20136682 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1758_CR17","doi-asserted-by":"publisher","unstructured":"Su, SF. et al. Genome-wide epigenetic landscape of lung adenocarcinoma links HOXB9 DNA methylation to intrinsic EGFR-TKI resistance and heterogeneous responses. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/po.20.00151 (2021).","DOI":"10.1200\/po.20.00151"},{"key":"1758_CR18","first-page":"4002","volume":"12","author":"T Hou","year":"2019","unstructured":"Hou, T. et al. Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45\u03b2 promoter. Int. J. Clin. Exp. Pathol. 12, 4002\u20134010 (2019).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"1758_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113771","volume":"43","author":"J Liang","year":"2024","unstructured":"Liang, J. et al. Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. Cell Rep. 43, 113771 (2024).","journal-title":"Cell Rep."},{"key":"1758_CR20","doi-asserted-by":"publisher","unstructured":"Kocy\u0142a A, Kr\u0119\u017cel A. Zinc-mediated dynamics of CD4\/CD8\u03b1 co-receptors and Lck kinase: implications for zinc homeostasis, immune response, and biotechnological innovations. Metallomics. https:\/\/doi.org\/10.1093\/mtomcs\/mfaf018 (2025).","DOI":"10.1093\/mtomcs\/mfaf018"},{"key":"1758_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0065-2776(08)00003-5","volume":"97","author":"T Hirano","year":"2008","unstructured":"Hirano, T., Murakami, M., Fukada, T., Nishida, K., Yamasaki, S. & Suzuki, T. Roles of zinc and zinc signaling in immunity: zinc as an intracellular signaling molecule. Adv. Immunol. 97, 149\u2013176 (2008).","journal-title":"Adv. Immunol."},{"key":"1758_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0041-008X(03)00219-9","volume":"191","author":"JM Samet","year":"2003","unstructured":"Samet, J. M., Dewar, B. J., Wu, W. & Graves, L. M. Mechanisms of Zn(2+)-induced signal initiation through the epidermal growth factor receptor. Toxicol. Appl. Pharm. 191, 86\u201393 (2003).","journal-title":"Toxicol. Appl. Pharm."},{"key":"1758_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0014-4827(03)00406-3","volume":"291","author":"H Haase","year":"2003","unstructured":"Haase, H. & Maret, W. Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin\/insulin-like growth factor-1 signaling. Exp. Cell Res. 291, 289\u2013298 (2003).","journal-title":"Exp. Cell Res."},{"key":"1758_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1165\/rcmb.2003-0233OC","volume":"30","author":"W Wu","year":"2004","unstructured":"Wu, W. et al. Heparin-binding epidermal growth factor cleavage mediates zinc-induced epidermal growth factor receptor phosphorylation. Am. J. Respir. Cell Mol. Biol. 30, 540\u2013547 (2004).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1758_CR25","first-page":"1","volume":"43","author":"D Kim","year":"2020","unstructured":"Kim, D., Lee, Y. S., Kim, D. H. & Bae, S. C. Lung cancer staging and associated genetic and epigenetic events. Mol. Cells 43, 1\u20139 (2020).","journal-title":"Mol. Cells"},{"key":"1758_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00362-8","volume":"10","author":"H Song","year":"2022","unstructured":"Song, H. et al. Biological roles of RNA m(5)C modification and its implications in cancer immunotherapy. Biomark. Res. 10, 15 (2022).","journal-title":"Biomark. Res."},{"key":"1758_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41586-021-03210-1","volume":"591","author":"W Xu","year":"2021","unstructured":"Xu, W. et al. METTL3 regulates heterochromatin in mouse embryonic stem cells. Nature 591, 317\u2013321 (2021).","journal-title":"Nature"},{"key":"1758_CR28","doi-asserted-by":"publisher","unstructured":"Quarto, G. et al. Fine-tuning of gene expression through the Mettl3\u2013Mettl14\u2013Dnmt1 axis controls ESC differentiation. Cell https:\/\/doi.org\/10.1016\/j.cell.2024.12.009 (2025).","DOI":"10.1016\/j.cell.2024.12.009"},{"key":"1758_CR29","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41588-022-01173-1","volume":"54","author":"S Deng","year":"2022","unstructured":"Deng, S. et al. RNA m(6)A regulates transcription via DNA demethylation and chromatin accessibility. Nat. Genet. 54, 1427\u20131437 (2022).","journal-title":"Nat. Genet."},{"key":"1758_CR30","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41588-023-01452-5","volume":"55","author":"T Sun","year":"2023","unstructured":"Sun, T., Xu, Y., Xiang, Y., Ou, J., Soderblom, E. J. & Diao, Y. Crosstalk between RNA m6A and DNA methylation regulates transposable element chromatin activation and cell fate in human pluripotent stem cells. Nat. Genet. 55, 1324\u20131335 (2023).","journal-title":"Nat. Genet."},{"key":"1758_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nature21373","volume":"543","author":"F Neri","year":"2017","unstructured":"Neri, F. et al. Intragenic DNA methylation prevents spurious transcription initiation. Nature 543, 72\u201377 (2017).","journal-title":"Nature"},{"key":"1758_CR32","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1016\/j.cell.2021.03.062","volume":"184","author":"M Mendel","year":"2021","unstructured":"Mendel, M. et al. Splice site m(6)A methylation prevents binding of U2AF35 to inhibit RNA splicing. Cell 184, 3125\u20133142.e25 (2021).","journal-title":"Cell"},{"key":"1758_CR33","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202010025","volume":"16","author":"L Fang","year":"2020","unstructured":"Fang, L. et al. CIGAR-seq, a CRISPR\/Cas-based method for unbiased screening of novel mRNA modification regulators. Mol. Syst. Biol. 16, e10025 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"1758_CR34","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/nar\/gkaa1193","volume":"49","author":"T Selmi","year":"2021","unstructured":"Selmi, T. et al. Sequence- and structure-specific cytosine-5 mRNA methylation by NSUN6. Nucleic Acids Res. 49, 1006\u20131022 (2021).","journal-title":"Nucleic Acids Res."},{"key":"1758_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.celrep.2015.12.043","volume":"14","author":"F Aguilo","year":"2016","unstructured":"Aguilo, F. et al. Deposition of 5-methylcytosine on enhancer RNAs enables the coactivator function of PGC-1\u03b1. Cell Rep. 14, 479\u2013492 (2016).","journal-title":"Cell Rep."},{"key":"1758_CR36","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1038\/s41388-021-01978-0","volume":"40","author":"J Su","year":"2021","unstructured":"Su, J. et al. NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization. Oncogene 40, 5814\u20135828 (2021).","journal-title":"Oncogene"},{"key":"1758_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.molcel.2017.11.031","volume":"69","author":"Y Zhu","year":"2018","unstructured":"Zhu, Y. et al. Molecular mechanisms for CFIm-mediated regulation of mRNA alternative polyadenylation. Mol. Cell 69, 62\u201374.e4 (2018).","journal-title":"Mol. Cell"},{"key":"1758_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01785-z","volume":"22","author":"V Ortiz-Barahona","year":"2023","unstructured":"Ortiz-Barahona, V. et al. Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer. Mol. Cancer 22, 83 (2023).","journal-title":"Mol. Cancer"},{"key":"1758_CR39","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1021\/acs.jproteome.8b00745","volume":"18","author":"EH Bowler","year":"2019","unstructured":"Bowler, E. H., Bell, J., Divecha, N., Skipp, P. & Ewing, R. M. Proteomic analysis of azacitidine-induced degradation profiles identifies multiple chromatin and epigenetic regulators including Uhrf1 and Dnmt1 as sensitive to azacitidine. J. Proteome Res. 18, 1032\u20131042 (2019).","journal-title":"J. Proteome Res."},{"key":"1758_CR40","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1093\/hmg\/ddab178","volume":"30","author":"P Xu","year":"2021","unstructured":"Xu, P. et al. UHRF1 regulates alternative splicing by interacting with splicing factors and U snRNAs in a H3R2me involved manner. Hum. Mol. Genet. 30, 2110\u20132122 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"1758_CR41","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/10428194.2016.1207767","volume":"58","author":"A Maiti","year":"2017","unstructured":"Maiti, A., Cortes, J. E., Brown, Y. D. & Kantarjian, H. M. Phase I\/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk. Lymphoma 58, 722\u2013725 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"1758_CR42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41392-023-01528-y","volume":"8","author":"R Liu","year":"2023","unstructured":"Liu, R., Zhao, E., Yu, H., Yuan, C., Abbas, M. N. & Cui, H. Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal Transduct. Target Ther. 8, 310 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1758_CR43","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa2119771","volume":"386","author":"YC Liu","year":"2022","unstructured":"Liu, Y. C. et al. Demethylation and up-regulation of an oncogene after hypomethylating therapy. N. Engl. J. Med. 386, 1998\u20132010 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1758_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03513-4","volume":"9","author":"JX Cheng","year":"2018","unstructured":"Cheng, J. X. et al. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat. Commun. 9, 1163 (2018).","journal-title":"Nat. Commun."},{"key":"1758_CR45","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1089\/ars.2014.6128","volume":"24","author":"Y Pan","year":"2016","unstructured":"Pan, Y. et al. Epigenetic upregulation of metallothionein 2A by diallyl trisulfide enhances chemosensitivity of human gastric cancer cells to docetaxel through attenuating NF-\u03baB activation. Antioxid. Redox Signal 24, 839\u2013854 (2016).","journal-title":"Antioxid. Redox Signal"},{"key":"1758_CR46","doi-asserted-by":"publisher","unstructured":"Zhang H, Wang H, Qin L, Lin S. Garlic-derived compounds: epigenetic modulators and their antitumor effects. Phytother Res. https:\/\/doi.org\/10.1002\/ptr.8108 (2024).","DOI":"10.1002\/ptr.8108"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01758-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01758-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01758-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:20:43Z","timestamp":1785810043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01758-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1758"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01758-4","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All mouse experiments were covered under a protocol approved by the Animal Ethics Committee of Beijing Chest Hospital (XK-2022-012). This study was conducted with ethical approval from the Institutional Review Board of Beijing Chest Hospital (Protocols JYS-2021-013 and JYS-2023-037). Written informed consent was obtained from each patient.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}